The final episode summarizes the human data on complement in ANCA vasculitis, with a quick discussion of the trials of C5a receptor antagonism.

Brought to you by Actemra.

• Intro :10
• Welcome :21
• Recap of previous episodes :22
• In this episode 2:12
• Let’s start with neutrophil data 5:24
• Studies in humans 11:54
• A summary of the data so far 21:20
• What does all this amount to? 25:41
• Trials of avacopan 28:25
• Side effect profile 36:25
• Thanks for listening 37:06

Disclosures: Brown reports no relevant financial disclosures.

We’d love to hear from you! Send your comments/questions to Dr. Brown at [email protected]. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum

References:

Augusto JF, et al. PLoS One. 2016;https://doi.org/10.1371/journal.pone.0158871.

Bekker P, et al. PLoS One. 2016;https://doi.org/10.1371/journal.pone.0164646.

Chen SF, et al. Arthritis Res Ther. 2015;https://doi.org/10.1186/s13075-015-0656-8.

Falk RJ, et al. Proc Natl Acad Sci USA. 1990;87:4115-4119.

Gou SJ, et al. Clin J Am Soc Nephrol. 2013;8:1884-1891.

Gou SJ, et al. Kidney Int. 2013;83:129-137.

Jayne DRW, et al. J Am Soc Nephrol. 2017;28:2756-2767.

Jayne DRW, et al. N Engl J Med. 2021;384:599-609.

Merkel PA, et al. ACR Open Rheumatol. 2020;2:662-671.

Schreiber A, et al. J Am Soc Nephrol. 2009;20:289-298.

Xiao H, et al. Am J Pathol. 2007;170:52-64.